Response to Comment on: Fraser et al. The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: A 24-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Diabetes Care 2012;35:1095–1097

We welcome the commentary of Ziegler et al. (1) and are delighted to have the opportunity to clarify certain details of the study that were included in our first submission but had to be omitted because of article length restrictions.We don’t agree with the statement that because the number of subjects included with confirmed diabetic sensorimotor polyneuropathy (DSPN) was presumably low, our trial does not provide information on whether benfotiamine may improve or slow progression of DSPN. We found that nerve conduction study (NCS) parameters deteriorated in both groups at the same speed/level as found in earlier publications for type 1 diabetes (2). Abnormal nerve conduction score was …